Pre-Open Stock Movers 08/17: (CVAC) (TCON) (GOLD) Higher; (SRNE) Lower (more...)

August 17, 2020 9:30 AM EDT
Get Alerts CVAC Hot Sheet
Price: $107.00 +4.54%

Overall Analyst Rating:
    NEUTRAL (Up Up)

Trade Now! 
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Today's Pre-Open Stock Movers:

CureVac B.V. (NASDAQ: CVAC) 41.8% HIGHER; After surging 249% on its IPO debut Friday, COVID-19 vaccine maker CureVac B.V. (NASDAQ: CVAC) is trading up again.

TRACON Pharmaceuticals (NASDAQ: TCON) 18.7% HIGHER; announced the clearance of the pivotal ENVASARC protocol after filing the protocol with the U.S. Food and Drug Administration (FDA) as part of an Investigational New Drug (IND) application on July 15. The application cross referenced the open envafolimab IND maintained by TRACONs corporate partners 3D Medicines and Alphamab Oncology. TRACON expects to initiate enrollment in the ENVASARC trial at 25 sites in the U.S. in the fourth quarter of 2020.

Sorrento Therapeutics (NASDAQ: SRNE) 12.2% LOWER; may be tied in part to news the FDA issued an emergency authorization of a saliva-based test for coronavirus developed at Yale University and funded by the NBA and the National Basketball Players Association.

Barrick Gold (NASDAQ: GOLD) 10.7% HIGHER; Warren Buffett's Berkshire Hathaway shocked Wall Street after the close Friday by disclosing a nearly 21 million share stake in the gold producer. The stake is worth approx $565 million, based on Friday's closing price.

Yintech Investment Holdings Limited (NASDAQ: YIN) 9.6% HIGHER; entered into a definitive Agreement and Plan of Merger (the "Merger Agreement") with Yinke Holdings Ltd ("Parent") and Yinke Merger Co. Ltd ("Merger Sub"), a wholly-owned subsidiary of Parent, pursuant to which the Company will be acquired by a group of rollover shareholders (the "Rollover Shareholders") in a transaction implying an equity value of the Company of approximately US$540.2 million (the "Merger"). The Rollover Shareholders include Mr. Wenbin Chen, co-founder, chairman of the board of directors (the "Board") and chief executive officer of Yintech, Mr. Ming Yan, co-founder and director of Yintech, Ms. Ningfeng Chen, co-founder and director of Yintech (collectively, the "Buyer Group"), and, certain other shareholders of the Company. The Rollover Shareholders have entered into a rollover and contribution agreement (the "Rollover Agreement"), pursuant to which each Rollover Shareholder will contribute the ordinary shares of the Company, with par value US$0.00001 per share (each, a "Share") held by him, her or it into Merger Sub immediately prior to the closing of the Merger in exchange for newly issued ordinary shares of Parent.

Principia Biopharma Inc. (NASDAQ: PRNB) 9.2% HIGHER; Sanofi (NYSE: SNY) and Principia Biopharma Inc. (NASDAQ: PRNB) entered into a definitive agreement under which Sanofi will acquire all of the outstanding shares of Principia for $100 per share in cash, which represents an aggregate equity value of approximately $3.68 billion (on a fully diluted basis). The Sanofi and Principia Boards of Directors unanimously approved the transaction.

Abeona Therapeutics Inc. (Nasdaq: ABEO) 9% HIGHER; The company and Taysha Gene Therapies, a patient-centric gene therapy company with a mission to eradicate monogenic CNS disease, today announced that they have entered into license and inventory purchase agreements for ABO-202, an adeno-associated virus (AAV) gene therapy for CLN1 disease (also known as infantile Batten disease). The agreements grant Taysha worldwide exclusive rights to intellectual property developed by scientists at the University of North Carolina at Chapel Hill (UNC) and Abeona, and Abeona know-how relating to the research, development, and manufacture of ABO-202. The therapy was originally developed in the lab of Steven Gray, Ph.D., Associate Professor at UT Southwestern Medical Center (formerly with UNC) and Chief Scientific Advisor for Taysha Gene Therapies. Abeona continued to progress the program, including development of the Phase 1/2 clinical trial protocol and manufacturing process, and received FDA clearance of its Investigational New Drug (IND) Application for a Phase 1/2 clinical trial that is anticipated to enter the clinic in 2021. (NASDAQ: OSTK) 7.4% HIGHER; Piper Sandler initiates coverage with an Overweight rating and a price target of $140.

OPKO Health (NASDAQ: OPK) 7% HIGHER; Jim Cramer said the company's Bio-Reference assisted in validating the COVID-19 saliva tests. (NASDAQ: JD) 4.4% HIGHER; reported Q2 EPS of $0.50, $0.12 better than the analyst estimate of $0.38. Revenue for the quarter came in at $28.5 billion versus the consensus estimate of $27.52 billion.

General Motors (NYSE: GM) 3% HIGHER; Deutsche Bank named General Motors (NYSE: GM) to the short-term Catalyst Call Buy List, as recent media coverage about a potential GM EV spinoff and CEO Mary Barra’s response to our question on the 2Q earnings call suggest GM is actively evaluating the option.

NVIDIA (NASDAQ: NVDA) 2.5% HIGHER; Susquehanna analyst Christopher Rolland raised the price target on NVIDIA (NASDAQ: NVDA) to a 'Street High' $540.00 (from $450.00) while maintaining a Positive rating into Q2 results and guidance after the close on Wednesday, August 1.

Novavax, Inc. (NASDAQ: NVAX) 2% HIGHER; announced the beginning of a Phase 2b clinical trial in South Africa to evaluate the efficacy of NVX-CoV2373, Novavax COVID-19 vaccine candidate. Dr. Shabir Madhi, Professor of Vaccinology at Wits University, will lead the clinical trial, which is supported in part by a $15 million grant from the Bill & Melinda Gates Foundation. NVXCoV2373 is a stable, prefusion protein made using Novavax proprietary nanoparticle technology and includes Novavax proprietary MatrixM adjuvant.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Special Reports

Related Entities

Jim Cramer, Warren Buffett, Deutsche Bank, Susquehanna International Group of Companies, Earnings, Bill & Melinda Gates Foundation Trust, Pre-Open Losers, Pre-Open Winners, Definitive Agreement, IPO, Pre Market Movers, FDA